GeNeuro SA Postpones Publication of June 30, 2025 Half-Yearly Financial Report

Geneva, Switzerland, 15 October 2025 – 6:00 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces the postponement of its June 30, 2025 half-yearly results and half-yearly financial report. This decision is in line with the postponement of the annual results for the fiscal year ended December 31, 2024, annual results and annual financial report in order to be able to take into account the financial impacts of the restructuring targeted by the Company as part of the debt-restructuring moratorium procedure extended on September 25. 2025. The Company will announce by press release the new date of their approval and publication.